RTS,S
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). , the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands.
18 million doses have been allocated for 2023–2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368850447 under CC BY-SA 4.0; modifications have been made.